Portrazza, in combination with gemcitabine and cisplatin, is the first biologic approved for first-line treatment of people with metastatic squamous non-small cell lung cancer
FDA Approves Portrazza™ (necitumumab) for Specific Type of Lung Cancer (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.